HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $57
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Joseph Pantginis maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $47 to $57.
HC Wainwright & Co. analyst Joseph Pantginis maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $47 to $57.